
Biogen inks royalty deal to gain funding for lupus drug R&D
Dive Brief: Biogen is set to receive as much as $250 million in funding to develop a late-stage experimental lupus medication called litifilimab after signing a deal with Royalty Pharma. In exchange, Royalty Pharma will receive unspecified payments if …